Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.

NCT04382768 is registered in ClinicalTrials.gov with Química Luar SRL as lead sponsor.

NCT NCT04382768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04382768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.
Lead sponsor
Química Luar SRL
Phase
Not applicable
Overall status
Unknown status
Start date
May 1, 2020
Completion date
January 31, 2021
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, respiratory disease, sars (disease)